Inclusion Criteria:
- Following diagnoses are eligible for inclusion in the study:
A) Multiple Myeloma with ASCT used as consolidation after first line induction therapy or at first relapse.
B) Relapsed/Refractory Hodgkin's disease
C) Non-Hodgkin's Lymphomas as follows
- Relapsed/Refractory Diffuse large B cell lymphoma
- Relapsed/Refractory indolent or relapsed/refractory transformed indolent B cell lymphomas as consolidation after second line therapy
- Mantle Cell lymphoma as consolidation after first-line therapy
- Peripheral T cell lymphoma as consolidation after first-line therapy or at relapse or primary refractory disease
- Patients undergoing first ASCT will be eligible for the study.
- Any prior therapy for the malignancy except CD38 antibody within the last 12 months is allowed.
- Age ≥18 years
- Life expectancy of greater than 6 months.
Exclusion Criteria:
- Previously exposure to a CD38 antibody during the last 12 months.
- Participants who are receiving any other investigational agents concurrently or received any investigational agent within the last 8 weeks.
- History of severe allergic reactions or anaphylaxis attributed to compounds of similar chemical or biologic composition to Isatuximab.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Pregnant and Lactating women